凝血因子VIIa及其抑制剂的研究进展

Research Progress on Coagulation Factor VIIa and Its Inhibitors

摘要: 凝血因子VIIa (FVIIa)是外源性凝血途径的关键启动因子，可与组织因子(TF)结合形成复合物，启动凝血级联反应，其异常激活与血栓形成、肿瘤进展等病理过程密切相关，是抗凝与抗肿瘤领域的重要靶点。文章系统综述了FVIIa的结构功能、TF-FVIIa复合物激活机制，总结国内外FVIIa抑制剂的研发进展、分子设计策略及构效关系，分析临床转化瓶颈与未来发展方向。研究表明，FVIIa依靠γ-羧基谷氨酸(Gla)、表皮生长因子样(EGF)、丝氨酸蛋白酶三个结构域协同完成膜结合、TF识别与催化激活；目前已开发出PCI-27483、KB-FVIIa-004、mAb4F5等代表性抑制剂，但受出血风险、口服生物利用度低、靶点特异性不足、临床试验终点未达标等问题限制，尚无药物成功上市；基于结构的药物设计、构象限制、特异性氢键与静电互补调控等策略，可显著提升抑制剂活性、选择性与成药性。研究为开发高选择性、低出血风险的FVIIa靶向药物提供了理论参考与研究思路。

Abstract: Coagulation factor VIIa (FVIIa) is a key initiator of the extrinsic coagulation pathway. It can bind to tissue factor (TF) to form a complex and initiate the coagulation cascade. Its abnormal activation is closely related to pathological processes such as thrombosis and tumor progression, making it an important target in the fields of anticoagulation and antitumor therapy. This paper systematically reviews the structure and function of FVIIa, the activation mechanism of the TF-FVIIa complex, summarizes the research progress, molecular design strategies, and structure-activity relationships of FVIIa inhibitors globally, and analyzes the clinical translation bottlenecks and future development directions. Studies have shown that FVIIa relies on three domains—the γ-carboxyglutamic acid (Gla) domain, the epidermal growth factor-like (EGF) domain, and the serine protease domain—to collaboratively complete membrane binding, TF recognition, and catalytic activation. At present, representative inhibitors including PCI-27483, KB-FVIIa-004, and mAb4F5 have been developed, but none of them has been successfully marketed due to limitations such as bleeding risk, low oral bioavailability, insufficient target specificity, and failure to meet clinical trial endpoints. Strategies including structure-based drug design, conformational restriction, specific hydrogen bonding, and electrostatic complementarity can significantly improve the activity, selectivity, and druggability of inhibitors. This research provides theoretical references and research ideas for the development of highly selective FVIIa-targeted drugs with low bleeding risk.